Adverum Biotechnologies is a gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Co. is focused on treating: alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), as well as wet age-related macular degeneration (wAMD). For the treatment of A1AT deficiency, Co. is advancing its product candidate ADVM-043, AAVrh.10-A1AT. For treatment of the rare disease HAE, Co. is advancing its product candidate ADVM-053, AAVrh.10-C1EI. For wAMD, Co. is advancing its product candidate ADVM-022, AAV.7m8-aflibercept. In addition, Co. is developing a gene therapy product candidate for the treatment of cardiomyopathy associated with Friedreich's ataxia. We show 21 historical shares outstanding datapoints in our coverage of ADVM's shares outstanding history.
Understanding the changing numbers of ADVM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADVM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADVM by allowing them to research ADVM shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
